Regulatory

Medical Device Establishment Licence (MDEL) holders need to know about annual licence review for 2023

Holders of an active medical device establishment licence (MDEL) must apply to have their licence reviewed every year before April 1 in order to continue doing business. Those with a suspended MDEL are exempt from applying. An annual licence review (ALR) ensures that MDEL holders are: Adhering to regulatory requirements Maintaining their licence information up […]

Regulatory

Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe

According to FDA regulations, if an applicant wishes to pursue approval of its Abbreviated New Drug Application (ANDA), applicant must submit all materials required to fully address all shortcomings in the Complete Response Letter (CRL) within one year of the CRL’s issuance. The applicant must submit a request for an extension on or before the […]

Regulatory Uncategorized

Revising ANDA Labeling Following Revision of the RLD Labeling

The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled “Revising abbreviated new drug applications (ANDAs) Labeling Following Revision of the reference listed drugs (RLDs).” In this guidance, FDA is providing information on How ANDA applicants and holders should monitor for changes to RLD labeling: The sponsor […]

eCTD submission

US FDA will be accepting eCTD submission with U.S. Regional DTD V3.3 only from 1st March 2022

The US Food and Drug Administration’s (FDA or Agency) has announced the date that they will no longer support electronic submissions using the Electronic Common Technical Document (eCTD) Backbone Files Specification for Module 1 Version 1.3, Comprehensive Table of Contents Headings and Hierarchy Version 1.2.2, U.S. Regional Document Type Definition (DTD) Version 2.01 after March 1, […]

Regulatory

Cross Labeling Oncology Drugs in Combination Regimens Draft Guidance Issued by FDA

Cross labeling guidance is in response to increasing requests from sponsors applying for oncology drugs intended to be used in combination regimens. The purpose of this guidance is to describe FDA’s current recommendations about including relevant information in labeling for oncology drugs approved for use in a combination regimen, including important considerations for cross labeling […]